Últimas noticias sobre Exscientia (NASDAQ:EXAI) Bolsa

Exscientia

Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.

Exscientia Plc - American Depositary Shares

Exscientia PLC

Exail Technologies SA

Exscientia Plc (EXAI) has released an update. Exscientia Plc has committed to an irrevocable undertaking favoring the acquisition of its issued and...

Exscientia Plc Backs Acquisition by Recursion Pharmaceuticals

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Exscientia Plc (EXAI – Research Report) today and set a price target of $5.70. Th...

Morgan Stanley Sticks to Their Hold Rating for Exscientia Plc (EXAI)

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug Discovery Stocks Portfolio by 6.6% on the day. 

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual sales in excess of $50B.

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Exscientia Plc (EXAI – Research Report), with a price ta...

Morgan Stanley Sticks to Its Hold Rating for Exscientia Plc (EXAI)

Exscientia Plc (EXAI) Receives a Hold from Morgan Stanley

Morgan Stanley Remains a Hold on Exscientia Plc (EXAI)

ABCL

ABSI

BSGM

EXAI

NVDA

RLAY

RXRX

SDGR

Press Releases

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Exscientia

Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout

Latest Updates of Viva Biotech's Portfolio Companies

General

Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates

Exscientia Business Update for Second Quarter and First Half 2024

Exscientia to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Opinion

AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting

AVAI

BLFY

GEHC

RLYB

TWST

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Annexon

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Celcuity

Emergent BioSolutions

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Neurogene

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

PureTech Health plc - American Depositary Shares

PureTech Health

Q32 Bio

Regenxbio

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Stoke Therapeutics

Savara

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Comments

Exscientia

Noticias

Últimas noticias sobre Exscientia (NASDAQ:EXAI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL